Hims & Hers vs IVIM Health: November 2026 prices compared
As of November 20, 2026, neither Hims & Hers nor IVIM Health printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
Hims & Hers and IVIM Health, measure by measure
| Measure | Hims & Hers | IVIM Health |
|---|---|---|
| Tirzepatide, month to month | — | from $192 (per month, starting-dose price) |
| Tirzepatide, lowest printed | — | $192 ($117 + $75 program fee) |
| Semaglutide, month to month | — | from $140 (per month, starting-dose price) |
| Semaglutide, lowest printed | — | $140 ($65 + $75 program fee) |
| Dose pricing | not confirmed | priced by dose or not stated |
| Membership or program fee | not confirmed | about $75 a month |
| Computed score | not scored (brand route) | 8 of 40 (position 18 of 27) |
| FDA warning letters | 716567 (2025-09-09); 716825 (2025-09-09) | 721816 (2026-02-20) |
| November 20 read | not readable Nov 20 | first-party read |
Strengths and limitations: which fits whom
Hims & Hers suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. IVIM Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| IVIM Health | tirzepatide | — | from $192 |
| IVIM Health | semaglutide | — | from $140 |
Regulatory record
FDA’s warning-letter index lists warning letter 716567 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) and warning letter 716825 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Hims & Hers; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Hims & Hers or IVIM Health?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do Hims & Hers and IVIM Health charge a membership fee?
Hims & Hers: not confirmed on November 20, 2026; IVIM Health: about $75 a month on top of medication. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Hims & Hers and IVIM Health medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Hims & Hers pricing page (not readable on November 20, 2026)
- IVIM Health pricing page (read November 20, 2026)
- FDA warning letter 716567 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)
- FDA warning letter 716825 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)
- FDA warning letter 721816 to IVIM Health (dated 2026-02-20, posted 2026-03-03)